Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Mark Adams who wrote (955)	4/17/2000 10:31:00 PM
From: Pseudo Biologist	Read Replies (2) \| Respond to of 52153

Mark, I have been researching IBPI for a while now and nibbled on some of it, falling knife?, today. The web site has quite a bit of information intrabiotics.com They got well over $100M in cash from the IPO, and with about 29M shares out, they have a market cap of about $200M. Two projects moving into phase III and a very solid business strategy IMO. One needs to examine the phase II more carefully before committing more capital, but it does look very interesting. If the Kramer (sic. or is this a joke I am missing? or is this someone different from Jim Cramer of TSC, or I did not watch enough NBC sitcoms? -g-) point of view re. recent issues prevails, we may see IBPI trading well below cash in the near future. One ray of hope, Warburg Dillon was not the lead underwriter of their IPO, though they participated big. Deutsche Banc Alex Brown was the leftmost name; expect old Kevin to come up with some good stuff as soon as legally possible. PB